The partnership will research the use of quantum technology to drive the identification of multi-gene biomarker discovery for oncology drug discovery.  Crown Bioscience (CrownBio) is a subsidiary of JSR Life Sciences and possesses extensive data bases and domain expertise while CQC has extensive experience in quantum computing, quantum algorithms, quantum machine learning. CQC’s quantum programming suites include t|ket>, an architecture agnostic quantum software stack and EUMEN, a software package designed to facilitate computational chemistry calculations. Crown Bioscience’s parent corporation, JSR Corporation, is an investor in CQC. The companies will analyze genetic data to identify cancer treatment biomarkers and drive the next generation of bioinformatics. For more on this announcement, you can view the news release on the CQC website located here.

February 25, 2021